Marta Sokolowska, Ph.D., is the Associate Director for Controlled Substances in FDA’s Center for Drug Evaluation and Research (CDER). In this position, she oversees the Controlled Substances Program (CSP), which comprises the Controlled Substance Staff (CSS) and the Controlled Substances Initiatives (CSI) group. CSS provides consultation throughout FDA on evaluation of abuse potential of drugs and advises on all matters related to domestic and international drug scheduling. The strategy group pursues activities and policies to identify, mitigate, and manage emerging issues with controlled substances to minimize risks associated with problematic use while enabling appropriate access to these products for medical use.
Dr. Sokolowska is a recognized expert in drug abuse liability and scheduling strategies. She has facilitated numerous initiatives to improve public health by advancing the science of assessing drug abuse liability. Prior to joining FDA, Dr. Sokolowska held senior clinical and medical leadership roles in the pharmaceutical industry. She earned her doctoral degree in psychology from McMaster University in Canada.